Why is $VRDN moving today? · SEC 8-K archive

$VRDN SEC Filing Alert & Real-Time AI Stock Impact Analysis

T0 SEO archive for $VRDN: filings appear instantly. AI score, direction and bullet analysis unlock publicly after 4 hours (VIP sees them live).

← All archive signals

FAQ: $VRDN filing catalyst

Why did $VRDN trigger an AI stock catalyst alert?

$VRDN triggered a Stock Catalyst AI alert on 2026-11-04 00:00:00 UTC for a SEC 8-K filing (AI Score: -2.0/10). Headline: Viridian Therapeutics Reports Q3 Net Loss of $101.2M Amid Lumvoa Commercialization. Key points: - Product revenue reached $24.7M from Lumvoa launch with >100 patients on therapy. - Net loss widened significantly to $101.2M (-$0.81/share) vs. $34.6M in Q3 2025 as SG&A climbed. - BLA submission for elegrobart remains targeted for Q1 2027.

How did $VRDN stock react after the SEC filing?

After the SEC 8-K for $VRDN, observed market reaction: T0 price $25.15. Past moves do not guarantee future results.

Where can I get real-time $VRDN SEC filing alerts?

Stock Catalyst AI pushes real-time SEC 8-K alerts for $VRDN via Telegram and the VIP Web Terminal from €10/month.

$VRDN

$VRDN – Viridian Therapeutics Reports Q3 Net Loss of $101.2M Amid Lumvoa Commercialization

Viridian Therapeutics, Inc.\DE

2026-11-04 00:00:00 UTC · SEC 8-K · All $VRDN

Unlocked archive · Analyzed in <2s at T0

Bearish AI Sentiment (-2.0 / 10)

Product revenue reached $24.7M from Lumvoa launch with >100 patients on therapy.
Net loss widened significantly to $101.2M (-$0.81/share) vs. $34.6M in Q3 2025 as SG&A climbed.
BLA submission for elegrobart remains targeted for Q1 2027.

Unlock Live VIP Terminal & Telegram – €10/mo Original filing →